


Ask a doctor about a prescription for CASPOFUNGINA LORIEN 70 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
Package Leaflet: Information for the User
Caspofungin Lorien 70 mg powder for concentrate for solution for infusion EFG
Caspofungin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
5 Storage of Caspofungin Lorien powder for concentrate for solution for infusion
What Caspofungin Lorien powder for concentrate for solution for infusion is
Caspofungin Lorien powder for concentrate for solution for infusion contains a medicine called caspofungin. This belongs to a group of medicines called antifungals.
What Caspofungin Lorien powder for concentrate for solution for infusion is used for
Caspofungin is used to treat the following infections in children, adolescents, and adults:
infections in your nose, sinuses, or lungs (called “invasive aspergillosis”) if other antifungal treatments have not worked or have caused side effects. This infection is caused by molds called Aspergillus.
How Caspofungin Lorien powder for concentrate for solution for infusion works
Caspofungin makes fungal cells fragile and prevents the fungus from growing properly. This prevents the infection from spreading and allows the body's natural defenses to get rid of the infection completely.
Do not use Caspofungin Lorien powder for concentrate for solution for infusion
If you are not sure, talk to your doctor, pharmacist, or nurse before you start using your medicine.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using Caspofungin Lorien powder for concentrate for solution for infusion if:
Caspofungin Lorien may also cause severe skin reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist, or nurse before you start using Caspofungin Lorien.
Using Caspofungin Lorien powder for concentrate for solution for infusion with other medicines
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines. This includes medicines that you buy without a prescription, including herbal medicines.
This is because Caspofungin Lorien may affect the way other medicines work. Other medicines may also affect the way Caspofungin Lorien works.
Tell your doctor, pharmacist, or nurse if you are taking any of the following medicines:
If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist, or nurse before you start using Caspofungin Lorien.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
There is no information to suggest that Caspofungin Lorien affects your ability to drive or use machines.
Caspofungin will always be prepared and given to you by a healthcare professional. You will be given Caspofungin:
Your doctor will decide how long you should be treated with Caspofungin and how much Caspofungin you should be given each day. Your doctor will monitor whether the effect of the medicine is adequate. If you weigh more than 80 kg, you may need a different dose.
Use in children and adolescents
The dose for children and adolescents may be different to the dose for adults.
If you use more Caspofungin Lorien powder for concentrate for solution for infusion than you should
Your doctor will decide how much Caspofungin you need and for how long each day. If you are worried that you may have been given too much Caspofungin, tell your doctor or nurse straight away.
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse straight away if you notice any of the following side effects – you may need urgent medical treatment:
As with any prescription medicine, some side effects may be serious. Ask your doctor for more information.
Other side effects in adults include:
Common: may affect up to 1 in 10 people:
Uncommon: may affect up to 1 in 100 people:
Other side effects in children and adolescents
Very common: may affect more than 1 in 10 people:
Common: may affect up to 1 in 10 people:
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date is the last day of the month stated.
Store and transport in a refrigerator (between 2°C and 8°C).
Once Caspofungin Lorien has been prepared, it should be used immediately. This is because it does not contain any preservative to prevent bacterial growth. Only a trained healthcare professional who has read the complete instructions should prepare the medicine (see “Instructions for reconstituting and diluting Caspofungin Lorien” below).
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Composition of Caspofungina Lorien
After reconstitution, each ml of concentrate contains 5.2 mg of caspofungin
Appearance of the Product and Container Content
Caspofungina Lorien is a compact powder, white to off-white in color.
Each container contains one vial of powder.
Marketing Authorization Holder
Laboratorios Lorien S.L
Av. Josep Tarradellas, 8. Ático 1ª
08029 Barcelona
Spain
Manufacturer
Laboratori Fundació DAU
C/ C, 12-14 Pol. Ind. Zona Franca
08040 Barcelona
Spain
This Medicinal Product is Authorized in the Member States of the European Economic Area under the Following Names:
Member State Name | Medicinal Product Name |
Netherlands | Caspofungine Regiomedica 50 mg & 70 mg, powder for concentrate for solution for infusion |
Germany | Caspofungin Regiomedica 50 mg & 70 mg powder for concentrate for solution for infusion |
Denmark | Caspofungin Regiomedica 50 mg & 70 mg powder for concentrate for infusion solution |
Spain | Caspofungina Lorien 50 mg & 70 mg, powder for concentrate for solution for perfusion EFG |
Finland | Kaspofungiinia Regiomedica 50 mg & 70 mg, powder for intermediate concentrate for infusion solution |
France | Caspofungine Regiomedica 50 mg & 70 mg, powder for solution to be diluted for perfusion |
Italy | Caspofungin Regiomedica |
Norway | Caspofungin Regiomedica |
Sweden | Kaspofungin Regiomedica |
United Kingdom | Caspofungin 50 mg & 70 mg powder for concentrate for solution for infusion |
Date of the Last Revision of this Leaflet: September 2016
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
------------------------------------------------------------------------------------------------------------------
This Information is Intended Exclusively for Healthcare Professionals:
Instructions for the Reconstitution and Dilution of Caspofungina Lorien 50 mg:
Reconstitution of Caspofungina Lorien 50 mg
DO NOT USE DILUENTS CONTAINING GLUCOSE, as Caspofungina Lorien is not stable in diluents containing glucose. DO NOT MIX OR CO-ADMINISTER Caspofungina Lorien WITH ANY OTHER MEDICINAL PRODUCT, as there are no data available on the compatibility of Caspofungina Lorien with other substances, additives, or intravenous medicinal products. The infusion solution should be inspected visually for the presence of solid particles or a change in color.
INSTRUCTIONS FOR USE IN ADULT PATIENTS
Step 1 Reconstitution of the Vials
To reconstitute the powder, bring the vial to room temperature and add aseptically 10.5 ml of water for injectable preparations. The concentration of the reconstituted vials will be 5.2 mg/ml.
The compact white to off-white lyophilized powder will dissolve completely. Mix gently until a clear, colorless, or slightly yellowish solution is obtained. The reconstituted solutions should be inspected visually for the presence of solid particles or a change in color. The reconstituted solution can be stored for a maximum of 24 hours at a temperature of 25 °C or below.
Step 2 Addition of Reconstituted Caspofungina Lorien to the Infusion Solution for the Patient
The diluents for the final infusion solution are: sodium chloride injection solution or Ringer's lactate solution. The infusion solution is prepared by adding aseptically the appropriate amount of reconstituted concentrate (as shown in the following table) to a 250 ml infusion bag or bottle. For daily doses of 50 mg or 35 mg, reduced volume infusions in 100 ml can be used if medically necessary. Do not use if the solution is turbid or has precipitated.
PREPARATION OF THE INFUSION SOLUTION IN ADULTS
DOSE* | Volume of Reconstituted Caspofungina Lorien to Transfer to an Intravenous Bag or Bottle | Standard Preparation(Reconstituted Caspofungina Lorien added to 250 ml) final concentration | Reduced Volume Infusion (Reconstituted Caspofungina Lorien added to 100 ml) final concentration |
50 mg | 10 ml | 0.20 mg/ml | - |
50 mg in reduced volume | 10 ml | - | 0.47 mg/ml |
35 mg for moderate hepatic impairment (from a 50 mg vial) | 7 ml | 0.14 mg/ml | - |
35 mg for moderate hepatic impairment (from a 50 mg vial) in reduced volume | 7 ml | - | 0.34 mg/ml |
*10.5 ml should be used for the reconstitution of all vials
INSTRUCTIONS FOR USE IN PEDIATRIC PATIENTS
Calculation of Body Surface Area (BSA) for Pediatric Dosing
Before preparing the infusion, calculate the patient's body surface area (BSA) using the following formula: (Mosteller's formula1)

Preparation of the 70 mg/m2Infusion for Pediatric Patients >3 Months (Using a 50 mg Vial)
Preparation of the 50 mg/m2Infusion for Pediatric Patients >3 Months (Using a 50 mg Vial)
Preparation Notes:
1 Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med1987 Oct 22;317(17): 1098 (letter)
Instructions for the Reconstitution and Dilution of Caspofungina Lorien 70 mg:
Reconstitution of Caspofungina Lorien 70 mg
DO NOT USE DILUENTS CONTAINING GLUCOSE, as Caspofungina Lorien is not stable in diluents containing glucose. DO NOT MIX OR CO-ADMINISTER Caspofungina Lorien WITH ANY OTHER MEDICINAL PRODUCT, as there are no data available on the compatibility of Caspofungina Lorien with other substances, additives, or intravenous medicinal products. The infusion solution should be inspected visually for the presence of solid particles or a change in color.
INSTRUCTIONS FOR USE IN ADULT PATIENTS
Step 1 Reconstitution of the Vials
To reconstitute the powder, bring the vial to room temperature and add aseptically 10.5 ml of water for injectable preparations. The concentration of the reconstituted vials will be 7.2 mg/ml.
The compact white to off-white lyophilized powder will dissolve completely. Mix gently until a clear, colorless, or slightly yellowish solution is obtained. The reconstituted solutions should be inspected visually for the presence of solid particles or a change in color. The reconstituted solution can be stored for a maximum of 24 hours at a temperature of 25 °C or below.
Step 2 Addition of Reconstituted Caspofungina Lorien to the Infusion Solution for the Patient
The diluents for the final infusion solution are: sodium chloride injection solution or Ringer's lactate solution. The infusion solution is prepared by adding aseptically the appropriate amount of reconstituted concentrate (as shown in the following table) to a 250 ml infusion bag or bottle. For daily doses of 50 mg or 35 mg, reduced volume infusions in 100 ml can be used if medically necessary. Do not use if the solution is turbid or has precipitated.
PREPARATION OF THE INFUSION SOLUTION IN ADULTS
DOSE* | Volume of Reconstituted Caspofungina Lorien to Transfer to an Intravenous Bag or Bottle | Standard Preparation(Reconstituted Caspofungina Lorien added to 250 ml) final concentration | Reduced Volume Infusion (Reconstituted Caspofungina Lorien added to 100 ml) final concentration |
70 mg | 10 ml | 0.28 mg/ml | Not recommended |
70 mg (from two 50 mg vials)** | 14 ml | 0.28 mg/ml | Not recommended |
35 mg for moderate hepatic impairment (from a 70 mg vial) | 5 ml | 0.14 mg/ml | 0.34 mg/ml |
*10.5 ml should be used for the reconstitution of all vials
**If the 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials
INSTRUCTIONS FOR USE IN PEDIATRIC PATIENTS
Calculation of Body Surface Area (BSA) for Pediatric Dosing
Before preparing the infusion, calculate the patient's body surface area (BSA) using the following formula: (Mosteller's formula2)

Preparation of the 70 mg/m2Infusion for Pediatric Patients >3 Months (Using a 70 mg Vial)
Preparation of the 50 mg/m2Infusion for Pediatric Patients >3 Months (Using a 70 mg Vial)
The daily maintenance dose should not exceed 70 mg, regardless of the calculated dose for the patient.
Preparation Notes:
2 Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med1987 Oct 22;317(17): 1098 (letter)
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CASPOFUNGINA LORIEN 70 mg POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION – subject to medical assessment and local rules.